Korea Investment CORP Sells 338,744 Shares of Abbott Laboratories $ABT

Korea Investment CORP lowered its stake in Abbott Laboratories (NYSE:ABT) by 25.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 984,713 shares of the healthcare product maker’s stock after selling 338,744 shares during the period. Korea Investment CORP’s holdings in Abbott Laboratories were worth $123,375,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Gator Capital Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter worth $3,612,000. Wealthspire Advisors LLC increased its position in shares of Abbott Laboratories by 22.7% in the fourth quarter. Wealthspire Advisors LLC now owns 47,396 shares of the healthcare product maker’s stock worth $5,938,000 after purchasing an additional 8,773 shares during the period. Allianz SE increased its position in shares of Abbott Laboratories by 5.6% in the fourth quarter. Allianz SE now owns 91,323 shares of the healthcare product maker’s stock worth $11,442,000 after purchasing an additional 4,824 shares during the period. Gerber Kawasaki Wealth & Investment Management increased its position in shares of Abbott Laboratories by 21.5% in the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,706 shares of the healthcare product maker’s stock worth $339,000 after purchasing an additional 478 shares during the period. Finally, Howland Capital Management LLC boosted its stake in Abbott Laboratories by 2.5% in the fourth quarter. Howland Capital Management LLC now owns 46,014 shares of the healthcare product maker’s stock valued at $5,765,000 after buying an additional 1,118 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $87.89 on Friday. The stock’s 50 day moving average is $91.46 and its 200 day moving average is $107.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market cap of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.50 and a beta of 0.63. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Analyst Ratings Changes

Several analysts recently weighed in on the company. Barclays reduced their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Leerink Partners reduced their price objective on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Oppenheimer reduced their price objective on Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Piper Sandler reduced their price objective on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.38.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.